argenex SE $ARGX Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lowered its stake in shares of argenex SE (NASDAQ:ARGX) by 15.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 167,189 shares of the company’s stock after selling 31,524 shares during the period. Goldman Sachs Group Inc.’s holdings in argenex were worth $140,597,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. American Century Companies Inc. lifted its stake in shares of argenex by 11.6% in the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after purchasing an additional 23,864 shares in the last quarter. Allianz Asset Management GmbH lifted its stake in shares of argenex by 21.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after purchasing an additional 645 shares in the last quarter. US Bancorp DE lifted its stake in shares of argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock valued at $5,217,000 after purchasing an additional 1,919 shares in the last quarter. Candriam S.C.A. lifted its stake in shares of argenex by 5.8% in the 3rd quarter. Candriam S.C.A. now owns 48,200 shares of the company’s stock valued at $35,550,000 after purchasing an additional 2,633 shares in the last quarter. Finally, Sands Capital Management LLC acquired a new position in shares of argenex in the 3rd quarter valued at about $12,262,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ARGX shares. Citizens Jmp lifted their price objective on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Finally, Robert W. Baird lifted their price objective on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Stock Performance

argenex stock opened at $891.32 on Monday. The stock’s 50 day moving average price is $794.90 and its 200 day moving average price is $812.60. The firm has a market capitalization of $55.43 billion, a PE ratio of 39.68, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. argenex SE has a one year low of $510.05 and a one year high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The firm had revenue of $1.31 billion for the quarter. On average, analysts forecast that argenex SE will post 26.25 earnings per share for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.